LeanGene's Involvement with COVID-19
2020
LeanGene is committed to provide the territorial market with innovative & high quality diagnostics products & services that meet and exceed the needs and expectations of our regional customers.
SARS-CoV-2 (COVID-19) diagnostics solutions has been our main focus since declared as a global public health emergency by the World Health Organization (WHO) on 30 January 2020 and a pandemic on 11 March 2020.
LeanGene provides complete & comprehensive solutions for the early detection of Novel Coronavirus; SARS-CoV-2 (reffered to as COVID-19). Full range including real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays, full automated integrated gene detection solutions as well as rapid IgG & IgM antibody detection. We also support scientists to accelerate their scientific discovery in COVID-19 Research.
Alongside the diagnostics & research solutions we provide, LeanGene formulates & conducts technical trainings on COVID-19 (theoretical & hands-on) explaining the virus history and behaviour, laboratory practices and techniques to sample handling and diagnostics assay processing, latest diagnostics techniques and facts/considerations towards COVID-19 testing.
Our technical training materials are CME accredited and all attendees provided with training certificates.
LeanGene so far has conducted more than 30 seminars & trainings on COVID-19 onsite and remotely via webinars to our territorial customers.
To date, LeanGene has installed around 40 full automated COVID-19 RT-PCR platforms in Jordan and another 80 platforms within its territorial coverage.
